Related Experiment Video
Updated: Jul 11, 2026
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
[Gemcitabine and non small-cell lung cancer]
Stéphane Vignot1, Benjamin Besse
1Service d'oncologie médicale, Groupe hospitalier Diaconesses-Croix Saint Simon, 18 rue du Sergent Bauchat, 75012 Paris.
Bulletin Du Cancer
|September 13, 2007
Summary
Gemcitabine is a key therapy for non-small cell lung cancer (NSCLC), offering improved survival when combined with other agents. Future research should focus on targeted therapies to further enhance treatment outcomes.
Area of Science:
- Oncology
- Pharmacology
Context:
- Non-small cell lung cancer (NSCLC) treatment has evolved significantly over the past decade.
- Third-generation chemotherapies, including gemcitabine, are now standard in various clinical settings for NSCLC.
Purpose:
- To review the established and emerging clinical applications of gemcitabine in non-small cell lung cancer.
- To discuss the role of gemcitabine in combination therapies and future directions.
Summary:
- Gemcitabine, vinorelbine, and taxanes combined with platinum compounds are widely used for NSCLC, from early-stage to metastatic disease.
- Current response rates in advanced NSCLC are around 30%, with a median survival of 10 months, necessitating further improvement.
- This review covers gemcitabine's use in advanced disease, adjuvant settings, and combinations with targeted agents like anti-angiogenics and EGFR inhibitors.
Impact:
- Highlights the current role and future potential of gemcitabine in non-small cell lung cancer management.
- Identifies areas for further investigation, including combination strategies and targeted therapies for improved patient outcomes.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...